Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert A Hauser

Showing results (161-170 of 266) with videos related to

Pageof 27
Sort By:
Journal of Parkinson'S Disease|August 5, 2017
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety StudyRobert A Hauser, Rajesh Pahwa, Caroline M Tanner, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 17, 2013
Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's diseaseStewart A Factor, Kenneth Wolski, Daniel M Togasaki, et al.
The Lancet. Neurology|March 15, 2013
Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trialRobert A Hauser, Ann Hsu, Sherron Kell, et al.
Human Genetics|April 17, 2003
Translocation breakpoint in two unrelated Tourette syndrome cases, within a region previously linked to the disorderFiona C Crawford, Ghania Ait-Ghezala, Mark Morris, et al.
Neurology|June 30, 2012
Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)Peter A Lewitt, Robert A Hauser, Mei Lu, et al.
Frontiers in Neurology|November 7, 2022
Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesiaRajesh Pahwa, Susan Fox, Robert A Hauser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 30, 2010
Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's diseaseRobert A Hauser, Anthony H V Schapira, Olivier Rascol, et al.
Toxins|March 26, 2025
Efficacy Remaining at Time of Requested Re-Treatment for Cervical Dystonia: A Potential New Treatment Paradigm with DaxibotulinumtoxinAAaron Ellenbogen, Robert A Hauser, Atul T Patel, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 30, 2010
Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's diseaseOlivier Rascol, Paolo Barone, Robert A Hauser, et al.
Parkinsonism & Related Disorders|April 17, 2024
OFF-times before, during, and after nighttime sleep periods in Parkinson's disease patients with motor fluctuations and the effects of opicapone: A post hoc analysis of diary data from BIPARK-1 and -2Robert A Hauser, Aleksandar Videnovic, Patrício Soares-da-Silva, et al.
Pageof 27

Showing results (161-170 of 266) with videos related to

Sort By:
Pageof 27
Journal of Parkinson'S Disease|August 5, 2017
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety StudyRobert A Hauser, Rajesh Pahwa, Caroline M Tanner, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 17, 2013
Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's diseaseStewart A Factor, Kenneth Wolski, Daniel M Togasaki, et al.
The Lancet. Neurology|March 15, 2013
Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trialRobert A Hauser, Ann Hsu, Sherron Kell, et al.
Human Genetics|April 17, 2003
Translocation breakpoint in two unrelated Tourette syndrome cases, within a region previously linked to the disorderFiona C Crawford, Ghania Ait-Ghezala, Mark Morris, et al.
Neurology|June 30, 2012
Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)Peter A Lewitt, Robert A Hauser, Mei Lu, et al.
Frontiers in Neurology|November 7, 2022
Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesiaRajesh Pahwa, Susan Fox, Robert A Hauser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 30, 2010
Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's diseaseRobert A Hauser, Anthony H V Schapira, Olivier Rascol, et al.
Toxins|March 26, 2025
Efficacy Remaining at Time of Requested Re-Treatment for Cervical Dystonia: A Potential New Treatment Paradigm with DaxibotulinumtoxinAAaron Ellenbogen, Robert A Hauser, Atul T Patel, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 30, 2010
Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's diseaseOlivier Rascol, Paolo Barone, Robert A Hauser, et al.
Parkinsonism & Related Disorders|April 17, 2024
OFF-times before, during, and after nighttime sleep periods in Parkinson's disease patients with motor fluctuations and the effects of opicapone: A post hoc analysis of diary data from BIPARK-1 and -2Robert A Hauser, Aleksandar Videnovic, Patrício Soares-da-Silva, et al.
Pageof 27